| AEZS-108
(AEterna Zentaris) |
LHRH-R |
endometrial
cancer |
[d-Lys6] LHRH |
amide |
doxorubicin |
phase
III |
NCT01767155 |
completed |
| EP-100 (Esperance Pharmaceuticals Inc.) |
LHRH-R |
ovarian
cancer |
LHRH |
amide |
lytic
peptide |
phase II |
NCT01485848 |
completed |
| ANG1005 (Angiochem, Inc.) |
LRP1 |
breast cancer
with brain metastases, leptomeningeal |
Angiopep-2 |
succinic acid ester |
paclitaxel |
phase III |
NCT03613181 |
active, not recruiting |
| NGR-hTNF (AGC Biologics SpA) |
CD13
neovasculature |
malignant pleural mesothelioma |
CNGRC |
amide |
hTNF |
phase III |
NCT01098266 |
completed |
| G-202 (GenSpera, Inc.) |
PSMA |
Solid tumors, HCC |
DγEγEγEE |
amide |
Thapsigargin |
phase II |
NCT01777594 |
completed |
| |
| BT8009 (BicycleTx Limited) |
Nectin-4 |
advanced solid tumor |
bicyclic peptide |
Val-Cit |
MMAE |
phase I/II |
NCT04561362 |
recruiting |
| |
|
urothelial Cancer |
|
|
|
phase II/III |
NCT06225596 |
recruiting |
| |
| PEN-221 (Tarveda Therapeutics) |
SSTR2 |
advanced neuroendocrine and small cell lung cancer |
octreotide |
disulfide |
DM1 |
phase I/II |
NCT02936323 |
completed |
| CBX-12 (Cybrexa Therapeutics) |
low pH and TOP1 |
platinum resistant or refractory ovarian cancer |
pHLIP |
disulfide |
Exatecan |
phase II |
NCT06315491 |
recruiting |
| BMTP-11 (M.D.
Anderson Cancer Center) |
IL-11Rα |
osteosarcoma and prostate cancer with bone metastasis |
CGRRAGGSC |
amide |
peptidomimetic D(KLAKLAK)2 |
phase I |
NCT00872157 |
completed |
| TH1902 (Theratechnologies) |
SORT1 |
advanced solid tumor |
TH19P01 |
succinic acid ester |
docetaxel |
phase
I |
NCT04706962 |
recruiting |
| BPP-PTX |
ACE |
TNBC |
EWPRPQIPP |
succinic acid |
paclitaxel |
preclinical |
preclinical |
preclinical |
| KCC-TGX |
HER2 |
prostate cancer |
KCCYSL |
self-cycling |
TGX-D1 |
preclinical |
preclinical |
preclinical |
| SAP-CPT |
integrin αVβ3 |
breast and bladder cancer |
RGD |
self-assembly |
camptothecin |
preclinical |
preclinical |
preclinical |
